Lazibat Ines, Šamija Radenka Kuzmanić, Rotim Krešimir
Acta Clin Croat. 2016 Mar;55(1):125-33. doi: 10.20471/acc.2016.55.01.18.
The treatment of multiple sclerosis (MS) is becoming more complex, especially with the expanding number of available therapies for relapsing forms of MS. Greater understanding of the degenerative aspects of MS pathogenesis is redefining treatment goals and creating new treatment strategies. The existing immunomodulation drugs (disease-modifying therapies, DMTs) used in MS treatment have shown only partial benefits in controlling disease progression, primarily by reducing the inflammation component. However, new therapies for MS have been shown to be effective in delaying disease progression by protecting against brain atrophy, which is considered the most important preindicator of future patient disability. The favorable effect on reducing brain atrophy suggests the potential neuroprotective or even neuroregenerative effects of new treatments, marking progress in the treatment of MS.
多发性硬化症(MS)的治疗正变得愈发复杂,尤其是随着复发型MS可用治疗方法数量的不断增加。对MS发病机制中退行性方面的更深入理解正在重新定义治疗目标并创造新的治疗策略。目前用于MS治疗的免疫调节药物(疾病修正疗法,DMTs)在控制疾病进展方面仅显示出部分益处,主要是通过减轻炎症成分。然而,已证明MS的新疗法可通过预防脑萎缩有效延缓疾病进展,脑萎缩被认为是未来患者残疾的最重要预测指标。对减少脑萎缩的有利作用表明新疗法具有潜在的神经保护甚至神经再生作用,标志着MS治疗取得了进展。